Galderma has announced that its injectable product — known as Sculptra — has received certification under the European Union's updated medical device regulations, which formally expands its approved use from facial applications to include several areas on the body, such as the buttocks, thighs, chest, and upper arms.
Sculptra is classified as a collagen-stimulating biostimulator. Galderma boasts this offering as a means of addressing concerns like skin laxity, volume loss, and the appearance of cellulite. The company cites clinical studies indicating patient-reported improvements in skin texture, firmness, and contour in these new treatment zones — the buttocks, thighs, chest, and upper arms.
This regulatory milestone is framed as part of a broader strategic commitment to innovation and meeting shifting patient preferences toward more comprehensive aesthetic treatments.
Image Credit: Galderma
What Makes This Trend Stand Out
- Expanded Injectable Use
- The broadened approval of injectables for non-traditional body areas opens new possibilities for aesthetic enhancement.
- Collagen-boosting Biostimulators
- The rise of biostimulators like Sculptra highlights a shift in focus towards natural-looking results in anti-aging treatments.
- Comprehensive Aesthetic Treatments
- A growing demand for multi-zone aesthetic treatments reflects a change in consumer preferences toward holistic beauty solutions.
Sectors Adopting This
- Medical Aesthetics
- Innovations in regulatory approval for injectables are revolutionizing the medical aesthetics industry by expanding available treatment options.
- Skincare and Dermatology
- The introduction of advanced collagen-stimulating products is transforming skincare practices within the dermatology field.
- Beauty and Wellness
- As consumers increasingly seek out all-encompassing treatment solutions, the beauty and wellness industry experiences a paradigm shift towards inclusivity and diversity in service offerings.
